Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Up 13.5% in June

Athira Pharma, Inc. (NASDAQ:ATHA) saw a significant increase in short interest in June. As of June 15th, there was short interest totalling 1,010,000 shares, an increase of 13.5% from the May 31st total of 889,500 shares. Based on an average trading volume of 173,900 shares, the days-to-cover ratio is currently 5.8 days. Currently, 2.9% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $19.00 price target on shares of Athira Pharma in a research note on Thursday, June 20th.

Insider Activity at Athira Pharma

In other Athira Pharma news, Director Kelly A. Romano bought 15,000 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The stock was bought at an average price of $2.26 per share, for a total transaction of $33,900.00. Following the completion of the acquisition, the director now directly owns 53,315 shares in the company, valued at $120,491.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Athira Pharma news, Director Kelly A. Romano bought 15,000 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The stock was bought at an average price of $2.26 per share, for a total transaction of $33,900.00. Following the completion of the acquisition, the director now directly owns 53,315 shares in the company, valued at $120,491.90. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kelly A. Romano bought 27,400 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were acquired at an average price of $2.42 per share, with a total value of $66,308.00. Following the acquisition, the director now owns 80,715 shares of the company’s stock, valued at $195,330.30. The disclosure for this purchase can be found here. 19.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Athira Pharma

A number of institutional investors have recently modified their holdings of ATHA. Perceptive Advisors LLC grew its stake in shares of Athira Pharma by 12.6% in the fourth quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock worth $13,129,000 after acquiring an additional 605,686 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Athira Pharma by 281.5% in the first quarter. Acadian Asset Management LLC now owns 549,938 shares of the company’s stock worth $1,505,000 after acquiring an additional 405,793 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Athira Pharma by 84.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company’s stock worth $1,363,000 after acquiring an additional 227,278 shares during the last quarter. Laird Norton Trust Company LLC grew its stake in shares of Athira Pharma by 21.3% in the third quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock worth $361,000 after acquiring an additional 31,400 shares during the last quarter. Finally, Mirador Capital Partners LP purchased a new stake in shares of Athira Pharma in the first quarter worth $57,000. 57.12% of the stock is owned by hedge funds and other institutional investors.

Athira Pharma Price Performance

ATHA stock traded up $0.02 during midday trading on Wednesday, hitting $2.54. The stock had a trading volume of 62,644 shares, compared to its average volume of 294,501. The firm has a market cap of $97.36 million, a price-to-earnings ratio of -0.87 and a beta of 2.91. The business has a 50-day moving average of $2.39 and a two-hundred day moving average of $2.72. Athira Pharma has a 52-week low of $1.33 and a 52-week high of $4.30.

Athira Pharma (NASDAQ:ATHA) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.11. Research analysts predict that Athira Pharma will post -2.79 earnings per share for the current year.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.